Nicole Anderson, APRN
Psychiatric/Mental Health · Stillwater, MNNPI 1902489339
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $187, 2.7 times the $70 reported in 2022.
Across 24 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$67
- Johnson & Johnson$49
- E.r. Squibb & Sons, L.L.C.$48
- Almatica Pharma LLC$44
- Alkermes, Inc.$44
- AbbVie$43
- plus $111 from 5 others
What the payments were for
- Food & beverage$406100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 5 | $67 |
| Johnson & Johnson | 2 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $48 |
| Almatica Pharma LLC | 3 | $44 |
| Alkermes, Inc. | 3 | $44 |
| AbbVie | 3 | $43 |
| Lundbeck LLC | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Cranial Technologies, Inc | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
How this compares
$406 in reported general payments places this provider in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $168,384 |
| Invega SustennaPaliperidone Palmitate | 22 | $81,847 |
| LybalviOlanzapine/Samidorphan Malate | 12 | $41,559 |
| RexultiBrexpiprazole | 23 | $31,221 |
| Risperdal ConstaRisperidone Microspheres | 13 | $18,957 |
| Aripiprazole | 186 | $11,656 |
| TrintellixVortioxetine Hydrobromide | 19 | $9,863 |
| Divalproex Sodium ErDivalproex Sodium | 76 | $5,863 |
| Duloxetine Hcl | 154 | $3,260 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 89 | $2,746 |
| Vilazodone Hcl | 40 | $2,723 |
| Paliperidone ErPaliperidone | 22 | $2,437 |
| Olanzapine | 106 | $2,418 |
| Naltrexone Hcl | 18 | $2,334 |
| Lamotrigine | 116 | $1,952 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $67 | $168,38420 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $49 | $100,80435 claims |
| Alkermes, Inc.Lybalvi | $44 | $41,55912 claims |
| Almatica Pharma LLCSertraline Hcl | $44 | $1,44796 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 407 psychiatric/mental health providers in Minnesota.
Other psychiatric/mental health in Stillwater
- Jacqualine GervaisMoorhead$29K
- Naomi KoenigSandstone$8K
- Dana BageonWayzata$7K
- Jill ScottAnoka$5K
- Holly WillisMinneapolis$5K
- Gerard BalanMinneapolis$5K
- Hilary BreedonShakopee$3K
- Tina AlexanderEdina$3K
- Twilla OskeyBaxter$3K
- Sara OckerCambridge$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.